Lab
MDX Diagnostics Laboratory
MDX Diagnostics Laboratory was paid $1.83M by Medicaid between Jul 2023 and Sep 2024, across 3 billing codes. Its largest line is 87913, — 100% of everything it billed.
33Billing provider infoMDX DIAGNOSTICS LABORATORY
HOUSTON, TX 77036
HOUSTON, TX 77036
33aNPI1417627308assigned 09/14/2021
33bProvider typeClinical Medical Laboratory
28Total paid$1.83M
24GClaims11,765
24DCodes billed3
24AFirst – last monthJul 2023 – Sep 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#48 of 436
Median peer was paid$17K
This provider vs. median106×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Single-Code Concentration100% of spending on code 87913 with only 3 total codes billed. Highly concentrated billing profile.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 909 | $0.00 | |
| 2024incomplete | 10,856 | $1.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87913 | 100% | 11,741 | 7,989 | $1.83M | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 12 | 12 | $0.00 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 12 | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPANCHAL, NAISHADH (PRESIDENT & OWNER)